Mylan move is a bit exaggerated after FDA drug approval: Analyst

1:26 PM ET Wed, 4 Oct 2017

CNBC's Meg Tirrell speaks with David Maris, Wells Fargo Securities senior analyst, about the generic competition between Mylan and Teva after Mylan gets approval for a generic MS drug.